{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:47:11Z","timestamp":1790689631116,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T00:00:00Z","timestamp":1509321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jaci.2017.10.005","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T12:50:57Z","timestamp":1512478257000},"page":"1509-1518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":211,"title":["Biomarkers for severe eosinophilic asthma"],"prefix":"10.1016","volume":"140","author":[{"given":"Steven W.","family":"Yancey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver N.","family":"Keene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank C.","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene R.","family":"Bleecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2017.10.005_bib1","unstructured":"Global Initiative For Asthma. Global strategy for asthma management and prevention, 2017. Available at: www.ginasthma.org. Accessed July 1, 2017."},{"key":"10.1016\/j.jaci.2017.10.005_bib2","series-title":"Omalizumab prescribing information","year":"2017"},{"key":"10.1016\/j.jaci.2017.10.005_bib3","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2147\/DDDT.S112208","article-title":"A review of omalizumab for the management of severe asthma","volume":"10","author":"Lin","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jaci.2017.10.005_bib4","series-title":"Omalizumab summary of product characteristics","year":"2015"},{"key":"10.1016\/j.jaci.2017.10.005_bib5","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1398-9995.2009.02119.x","article-title":"Relationship between pretreatment specific IgE and the response to omalizumab therapy","volume":"64","author":"Wahn","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.10.005_bib6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.03.00027302","article-title":"Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions","volume":"21","author":"Buttner","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2017.10.005_bib8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mai.2003.1382","article-title":"Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics","volume":"111","author":"Menzies-Gow","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.10.005_bib11","series-title":"Mepolizumab prescribing information","year":"2017"},{"key":"10.1016\/j.jaci.2017.10.005_bib12","series-title":"Mepolizumab summary of product characteristics","year":"2016"},{"key":"10.1016\/j.jaci.2017.10.005_bib13","series-title":"Reslizumab summary of product characteristics","year":"2016"},{"key":"10.1016\/j.jaci.2017.10.005_bib14","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.10.005_bib15","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.10.005_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1517\/14712598.2012.642359","article-title":"Benralizumab\u2014a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity\u2014a novel approach for the treatment of asthma","volume":"12","author":"Ghazi","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaci.2017.10.005_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib18","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.10.005_bib20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib21","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib22","article-title":"Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study","author":"Albers","year":"2017","journal-title":"J Asthma"},{"key":"10.1016\/j.jaci.2017.10.005_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2017.10.005_bib24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/bcp.12559","article-title":"Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects","volume":"79","author":"Moore","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2017.10.005_bib25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/eurheartj\/ehs432","article-title":"New technologies, new therapies: toward personalized medicine in heart failure patients?","volume":"34","author":"de Groote","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaci.2017.10.005_bib26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejca.2017.01.017","article-title":"Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM)","volume":"75","author":"Duffy","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaci.2017.10.005_bib27","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3819","article-title":"The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients","volume":"14","author":"Raterman","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2017.10.005_bib28","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.bbadis.2012.12.014","article-title":"Biomarkers and diagnostics in heart failure","volume":"1832","author":"Gaggin","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jaci.2017.10.005_bib29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1164\/ajrccm.161.1.9802048","article-title":"The relationship between airways inflammation and asthma severity","volume":"161","author":"Louis","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1067\/mai.2001.119411","article-title":"Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma","volume":"108","author":"Woodruff","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.10.005_bib32","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","article-title":"Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics","volume":"160","author":"Wenzel","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.healun.2010.08.027","article-title":"Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure","volume":"30","author":"Gheorghiade","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jaci.2017.10.005_bib34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2006.08.003","article-title":"Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes","volume":"118","author":"Lemiere","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.10.005_bib35","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1046\/j.1365-2222.2002.01477.x","article-title":"Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition","volume":"32","author":"Chu","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2017.10.005_bib36","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1046\/j.1365-2222.1997.890900.x","article-title":"Comparison of inflammatory cell counts in asthma: induced sputum vs bronchoalveolar lavage and bronchial biopsies","volume":"27","author":"Grootendorst","year":"1997","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2017.10.005_bib37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1164\/ajrccm.155.2.9032177","article-title":"Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects","volume":"155","author":"Keatings","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1513\/AnnalsATS.201310-354OC","article-title":"Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma","volume":"11","author":"Katz","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaci.2017.10.005_bib39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaci.2015.05.039","article-title":"Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma","volume":"136","author":"Ortega","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.10.005_bib40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1067\/mai.2001.116576","article-title":"Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys","volume":"108","author":"Hart","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.10.005_bib41","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0140-6736(15)00157-9","article-title":"Targeting the interleukin pathway in the treatment of asthma","volume":"386","author":"Chung","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.10.005_bib42","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.5414\/CP202446","article-title":"Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab","volume":"53","author":"Pouliquen","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2017.10.005_bib43","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib44","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.10.005_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jaci.2017.10.005_bib46","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.10.005_bib47","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib48","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib49","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jaci.2016.08.008","article-title":"Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma","volume":"139","author":"Yancey","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.10.005_bib50","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib51","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib52","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/1753465816667659","article-title":"The clinical profile of benralizumab in the management of severe eosinophilic asthma","volume":"10","author":"Menzella","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaci.2017.10.005_bib53","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1080\/03007995.2017.1347091","article-title":"The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies","volume":"33","author":"Goldman","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaci.2017.10.005_bib54","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.10.005_bib55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib56","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2017.10.005_bib57","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib58","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2003.10.041","article-title":"Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation","volume":"113","author":"Miranda","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.10.005_bib60","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)","volume":"108","author":"Schleich","year":"2014","journal-title":"Respir Med"},{"issue":"suppl","key":"10.1016\/j.jaci.2017.10.005_bib61","first-page":"A124","article-title":"P98 The relationship between invasive\u00a0and non-invasive measures of inflammation in children with severe therapy-resistant asthma","volume":"70","author":"McKeon","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2017.10.005_bib62","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jaci.2014.09.034","article-title":"High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma","volume":"135","author":"Fowler","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.10.005_bib63","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2013.03.044","article-title":"Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects","volume":"132","author":"Hastie","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl\u00a060","key":"10.1016\/j.jaci.2017.10.005_bib64","first-page":"PA1110","article-title":"Blood eosinophil dose response to oral corticosteroids in a population of patients with severe asthma","volume":"48","author":"Austin","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2017.10.005_bib65","first-page":"A4338","article-title":"A blood eosinophil count of greater than 150 cells\/uL predicts sputum eosinophilia \u22653% in patients with severe asthma with other markers of inflammatory lung disease","volume":"193","author":"Austin","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib66","first-page":"A1363","article-title":"Oral corticosteroid dose modulation in severe asthma: impact on peripheral blood eosinophil count","volume":"195","author":"Prazma","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib67","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S2213-2600(15)00050-8","article-title":"Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis","volume":"3","author":"Korevaar","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib68","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1513\/AnnalsATS.201507-443LE","article-title":"Reproducibility of a single blood eosinophil measurement as a biomarker in severe eosinophilic asthma","volume":"12","author":"Ortega","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaci.2017.10.005_bib69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1155\/2002\/929274","article-title":"Overview of biomarkers and surrogate endpoints in drug development","volume":"18","author":"Wagner","year":"2002","journal-title":"Dis Markers"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2017.10.005_bib70","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc17-S005","article-title":"2. Classification and diagnosis of diabetes","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaci.2017.10.005_bib71","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2337\/dc11-9997","article-title":"Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus","volume":"34","author":"Sacks","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaci.2017.10.005_bib72","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.110.943860","article-title":"Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact","volume":"123","author":"Pletcher","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jaci.2017.10.005_bib73","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2013.04.052","article-title":"Severe adult-onset asthma: a distinct phenotype","volume":"132","author":"Amelink","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.10.005_bib74","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.10.005_bib75","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","article-title":"High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma","volume":"2","author":"Zeiger","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.10.005_bib76","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1476-5381.2011.01219.x","article-title":"Cytokine\/anti-cytokine therapy\u2014novel treatments for asthma?","volume":"163","author":"Hansbro","year":"2011","journal-title":"Br J Pharmacol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917316512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917316512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:07:19Z","timestamp":1758791239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917316512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0091674917316512"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2017.10.005","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers for severe eosinophilic asthma","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2017.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}